Association between common risk factors and molecular subtypes in breast cancer patients

Breast

Volumn 22, Issue 3, 2013, Pages 344-350

  Turkoz, Fatma P ^a   Solak, Mustafa ^b   Petekkaya, Ibrahim ^b   Keskin, Ozge ^b   Kertmen, Neyran ^b   Sarici, Furkan ^b   Arik, Zafer ^b   Babacan, Taner ^b   Ozisik, Yavuz ^b   Altundag, Kadri ^b  

^a Ankara Oncology Research and Training Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Molecular subtypes; Risk factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; BREAST CANCER; BREAST FEEDING; CROSS-SECTIONAL STUDY; FAMILY HISTORY; FEMALE; FERTILIZATION IN VITRO; HANDEDNESS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MENARCHE; MENOPAUSE; NULLIPARA; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; TRIPLE NEGATIVE BREAST CANCER;

EID: 84877142910     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.08.005     Document Type: Article

References (35)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008. Globocan 2008. International Journal of Cancer 2010, 127:2893-2917.
2. McPherson K., Steel C.M., Dixon J.M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. British Medical Journal 2000, 321:624-628.
3. Huang W.Y., Newman B., Millikan R.C., Schell M.J., Hulka B.S., Moorman P.G. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. American Journal of Epidemiology 2000, 151:703-714.
4. Britton J.A., Gammon M.D., Schoenberg J.B., Stanford J.L., Coates R.J., Swanson C.A., et al. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. American Journal of Epidemiology 2002, 156:507-516.
5. Kwan M.L., Kushi L.H., Weltzien E., Maring B., Kutner S.E., Fulton R.S., et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Research 2009, 11:R31.
6. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006 Jun 7, 295:2492-2502.
7. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the Natural Academy of Sciences 2001, 98:10,869-10,874.
8. Millikan R.C., Newman B., Tse C.K., Moorman P.G., Conway K., Dressler L.G., et al. Epidemiology of basal-like breast cancer. Breast Cancer Research Treatment 2008, 109:123-139.
9. Yang X.R., Sherman M.E., Rimm D.L., Lissowska J., Brinton L.A., Peplonska B., et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiology, Biomarkers & Prevention 2007, 16:439-443.
10. Phipps A.I., Malone K.E., Porter P.L., Daling J.R., Li C.I. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 2008, 17:2078-2086.
11. Phipps A.I., Malone K.E., Porter P.L., Daling J.R., Li C.I. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008, 113:1521-1526.
12. Cotterchio M., Kreiger N., Theis B., Sloan M., Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiology, Biomarkers & Prevention 2003, 12:1053-1060.
13. Ma H., Bernstein L., Pike M.C., Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Research 2006, 8:R43.
14. World Health Organization Obesity-preventing and managing the global epidemic: report of a WHO expert committee 1998, World Health Organization, Geneva.
15. Colditz G.A., Rosner B.A., Chen W.Y., Holmes M.D., Hankinson S.E. Risk factors for breast cancer according to estrogen and progesterone receptor status. Journal of Natural Cancer Institute 2004, 96:218-228.
16. Althuis M.D., Fergenbaum J.H., Garcia-Closas M., Brinton L.A., Madigan M.P., Sherman M.E. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiology, Biomarkers & Prevention 2004, 13:1558-1568.
17. Milne R.L., Gaudet M.M., Spurdle A.B., Fasching P.A., Couch F.J., Benítez J., et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research 2010, 12:R110.
18. Lambe M., Hsieh C., Trichopoulos D., Ekbom A., Pavia M., Adami H.O. Transient increase in the risk of breast cancer after giving birth. New England Journal of Medicine 1994, 331:5-9.
19. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96973 women without the disease. Lancet 2002, 360:187-195. Collaborative Group on Hormonal Factors in Breast Cancer.
20. Iversen A., Thune I., McTiernan A., Emaus A., Finstad S.E., Flote V., et al. Ovarian hormones and reproductive risk factors for breast cancer in premenopausal women: the Norwegian EBBA-I study. Human Reproduction 2011, 26:1519-1529.
21. Li C.I., Malone K.E., Daling J.R., Potter J.D., Bernstein L., Marchbanks P.A., et al. Timing of menarche and first full-term birth in relation to breast cancer risk. American Journal of Epidemiology 2008, 167:230-239.
22. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427. Million Women Study Collaborators.
23. Holli K., Isola J., Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. Journal of Clinical Oncology 1998, 16:3115-3120.
24. Marchbanks P.A., McDonald J.A., Wilson H.G., Folger S.G., Mandel M.G., Daling J.R., et al. Oral contraceptives and the risk of breast cancer. New England Journal of Medicine 2002, 346:2025-2032.
25. Breast cancer and hormonal contraceptives: further results. Contraception 1996, 54:1S-106S. Collaborative Group on Hormonal Factors in Breast Cancer.
26. Kroenke C.H., Chen W.Y., Rosner B., Holmes M.D. Weight, weight gain, and survival after breast cancer diagnosis. Journal of Clinical Oncology 2005, 23:1370-1378.
27. Probst-Hensch N.M., Steiner J.H., Schraml P., Varga Z., Zurrer-Hardi U., Storz M., et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research 2010, 16:1025-1032.
28. Vona-Davis L., Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-Related Cancer 2007, 14:189-206.
29. Hamajima N., Hirose K., Tajima K., Rohan T., Calle E.E., Heath C.W., et al. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. British Journal of Cancer 2002, 87:1234-1245. Collaborative Group on Hormonal Factors in Breast Cancer.
30. Luo J., Margolis K.L., Wactawski-Wende J., Horn K., Messina C., Stefanick M.L., et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. British Medical Journal 2011, 342:d1016.
31. Chappuis P.O., Nethercot V., Foulkes W.D. Clinico-pathological characteristics of BRCA-1 and BRCA-2 related breast cancer. Seminars in Surgical Oncology 2000, 18:287-295.
32. Lakhani S.R., Van De Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. Journal of Clinical Oncology 2002, 20:2310-2318.
33. Russo A., Herd-Smith A., Gestri D., Bianchi S., Vezzosi V., Rosselli Del Turco M., et al. Does family history influence survival in breast cancer cases?. International Journal of Cancer 2002, 99:427-430.
34. Begg C.B., Zhang Z.F. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiology, Biomarkers & Prevention 1994, 3:173-175.
35. Critchley-Thorne R.J., Miller S.M., Taylor D.L., Lingle W.L. Applications of cellular systems biology in breast cancer patient stratification and diagnostics. Combinatorial Chemistry & High Throughput Screening 2009 Nov, 12(9):860-869.